Related Experiment Videos
Plasma tenoxicam concentrations after single and multiple oral doses.
C Crevoisier1, P Heizmann, I Forgo
1Pharma Clinical Research Department, F. Hoffmann-La Roche & Co., Basle, Switzerland.
European Journal of Drug Metabolism and Pharmacokinetics
|January 1, 1989
Summary
This study evaluated tenoxicam pharmacokinetics in healthy males. Tenoxicam (20 mg) showed linear pharmacokinetics, with steady-state concentrations reached after 10 daily doses.
Area of Science:
- Pharmacology
- Clinical Pharmacy
Background:
- Tenoxicam is a non-steroidal anti-inflammatory drug (NSAID).
- Understanding its pharmacokinetic profile is crucial for effective dosing.
Purpose of the Study:
- To evaluate the pharmacokinetics of single and multiple doses of tenoxicam (20 mg).
- To assess drug accumulation and linearity of pharmacokinetics over time.
Main Methods:
- 8 healthy male subjects received tenoxicam 20 mg daily for 10 days.
- Plasma concentrations were measured over time to determine pharmacokinetic parameters.
Main Results:
- Single dose: Cmax 2.76 µg/ml, Tmax 5.0 h, AUC 242.5 µg*h/ml, t1/2 66.3 h.
- Multiple doses (steady-state): Cmax 13.63 µg/ml, Tmax 5.0 h, AUC 262.2 µg*h/ml, t1/2 74.2 h.
- Linear pharmacokinetics were observed, with parameters slightly underestimated when predicted from single-dose data.
Conclusions:
- Tenoxicam (20 mg) exhibits linear pharmacokinetics in healthy males.
- Steady-state plasma concentrations are achieved after approximately 10 daily doses.
- The pharmacokinetic parameters support consistent therapeutic effects with multiple dosing.